Stratos Wealth Partners LTD. Has $11.01 Million Stake in Zoetis Inc. (NYSE:ZTS)

Stratos Wealth Partners LTD. lifted its holdings in shares of Zoetis Inc. (NYSE:ZTS) by 0.7% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 67,562 shares of the company’s stock after purchasing an additional 478 shares during the quarter. Stratos Wealth Partners LTD.’s holdings in Zoetis were worth $11,008,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the business. Cherry Creek Investment Advisors Inc. boosted its stake in shares of Zoetis by 2.0% in the 3rd quarter. Cherry Creek Investment Advisors Inc. now owns 3,021 shares of the company’s stock valued at $590,000 after purchasing an additional 58 shares in the last quarter. Grove Bank & Trust boosted its position in Zoetis by 0.5% during the 3rd quarter. Grove Bank & Trust now owns 11,763 shares of the company’s stock worth $2,298,000 after buying an additional 61 shares during the period. Hancock Whitney Corp increased its position in Zoetis by 0.3% in the 3rd quarter. Hancock Whitney Corp now owns 18,569 shares of the company’s stock valued at $3,628,000 after acquiring an additional 61 shares during the period. Strategy Asset Managers LLC increased its holdings in Zoetis by 3.5% in the third quarter. Strategy Asset Managers LLC now owns 1,822 shares of the company’s stock valued at $356,000 after purchasing an additional 62 shares during the period. Finally, Procyon Advisors LLC raised its position in shares of Zoetis by 1.4% during the fourth quarter. Procyon Advisors LLC now owns 4,712 shares of the company’s stock worth $768,000 after acquiring an additional 63 shares during the last quarter. Institutional investors own 92.80% of the company’s stock.

Zoetis Trading Up 0.2 %

Shares of Zoetis stock opened at $172.24 on Wednesday. The company has a debt-to-equity ratio of 1.26, a quick ratio of 2.27 and a current ratio of 3.69. The stock has a market capitalization of $77.71 billion, a P/E ratio of 32.38, a P/E/G ratio of 2.72 and a beta of 0.90. Zoetis Inc. has a 52-week low of $144.80 and a 52-week high of $200.53. The stock’s 50-day simple moving average is $169.48 and its 200 day simple moving average is $179.39.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Monday, November 4th. The company reported $1.58 EPS for the quarter, beating analysts’ consensus estimates of $1.46 by $0.12. Zoetis had a net margin of 26.55% and a return on equity of 51.98%. The company had revenue of $2.40 billion for the quarter, compared to analysts’ expectations of $2.29 billion. During the same period in the prior year, the company posted $1.36 EPS. Zoetis’s revenue was up 11.6% compared to the same quarter last year. As a group, research analysts anticipate that Zoetis Inc. will post 5.9 EPS for the current year.

Zoetis Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, January 21st will be issued a $0.50 dividend. This is a positive change from Zoetis’s previous quarterly dividend of $0.43. This represents a $2.00 dividend on an annualized basis and a dividend yield of 1.16%. The ex-dividend date of this dividend is Tuesday, January 21st. Zoetis’s dividend payout ratio (DPR) is presently 37.59%.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Morgan Stanley dropped their target price on shares of Zoetis from $248.00 to $243.00 and set an “overweight” rating on the stock in a report on Wednesday, January 29th. JPMorgan Chase & Co. boosted their target price on Zoetis from $225.00 to $230.00 and gave the company an “overweight” rating in a research report on Friday, October 11th. UBS Group started coverage on shares of Zoetis in a research report on Monday, December 9th. They issued a “neutral” rating and a $196.00 price target for the company. Leerink Partnrs raised Zoetis to a “strong-buy” rating in a research note on Monday, December 2nd. Finally, Stifel Nicolaus lowered their target price on shares of Zoetis from $210.00 to $180.00 and set a “buy” rating for the company in a report on Tuesday, January 7th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Buy” and an average price target of $215.00.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.